modelLosartanAndDiuretics
Extends from Pharmacolibrary.Drugs.ATC.C.C09DA01.
Information
| name: | LosartanAndDiuretics | |
| ATC code: | C09DA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 34.3 | L |
| clearance: | 44.1 | L/h |
| other parameters in model implementation | ||
Losartan and diuretics (typically losartan combined with hydrochlorothiazide) is an antihypertensive combination therapy used in the treatment of high blood pressure. Losartan is an angiotensin II receptor blocker (ARB) while hydrochlorothiazide is a thiazide diuretic; together, they provide a synergistic effect in reducing blood pressure. This combination is approved and widely used in clinical practice for hypertension management.
Pharmacokinetics
Pharmacokinetic estimates are provided for healthy adult subjects after oral administration of losartan in combination with a thiazide diuretic (hydrochlorothiazide). No published studies specifically reporting PK compartmental modeling parameters for the fixed-dose combination product. Estimates based on monograph and available data for the combination.
References
Kumar, S, et al., & Kurachi, K (2014). Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. International journal of clinical pharmacology and therapeutics 52(1) 39–54. DOI:10.5414/CP201927 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24290414
Sherazi, AW, et al., & Rasool, MF (2024). A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. Therapeutic drug monitoring 46(3) 309–320. DOI:10.1097/FTD.0000000000001141 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38176856
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)